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PUMAPancreatic cancer is an exceedingly lethal disease with a ﬁve-year survival that ranks among the lowest of
gastrointestinal malignancies. Part of its lethality is attributable to a generally poor response to existing che-
motherapeutic regimens. New therapeutic approaches are urgently needed. We aimed to elucidate the anti-
neoplastic mechanisms of apigenin—an abundant, naturally-occurring plant ﬂavonoid—with a particular
focus on p53 function. Pancreatic cancer cells (BxPC-3, MiaPaCa-2) experienced dose and time-dependent
growth inhibition and increased apoptosis with apigenin treatment. p53 post-translational modiﬁcation, nu-
clear translocation, DNA binding, and upregulation of p21 and PUMA were all enhanced by apigenin treat-
ment despite mutated p53 in both cell lines. Transcription-dependent p53 activity was reversed by
piﬁthrin-α, a speciﬁc DNA binding inhibitor of p53, but not growth inhibition or apoptosis suggesting
transcription-independent p53 activity. This was supported by immunoprecipitation assays which demon-
strated disassociation of p53/BclXL and PUMA/BclXL and formation of complexes with Bak followed by cyto-
chrome c release. Treated animals grew smaller tumors with increased cellular apoptosis than those fed
control diet. These results suggest that despite deactivating mutation, p53 retains some of its function
which is augmented following treatment with apigenin. Cell cycle arrest and apoptosis induction may be me-
diated by transcription-independent p53 function via interactions with BclXL and PUMA. Further study of ﬂa-
vonoids as chemotherapeutics is warranted.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic cancer is a dismal diagnosis with a 5-year survival of
only 5%. The lethality of pancreatic cancer is attributable to its ex-
ceedingly malignant biology with early metastatic spread to lymph
nodes and distant organs such as the liver and lungs as well as to its
aggressive local invasiveness. Furthermore, patients tend to present
late in the disease progression at a time when extirpative surgery—
currently the only potentially curative therapy—is not feasible. Che-
motherapeutic regimens based on gemcitabine offer little potential
for improved survival with randomized controlled studies demon-
strating only a ﬁve-week survival beneﬁt versus control patients [1].
New therapeutics capable of extending survival and down-staging
otherwise inoperable tumors in the neoadjuvant setting are urgently
needed in order to improve both survival and quality of life for pan-
creatic cancer patients.avid Geffen School of Medicine
fax: +1 310 206 2472.
s).
rights reserved.In response to this need recent basic science and translational research
has identiﬁed naturally-occurring plant polyphenols such as apigenin as
attractive candidate chemotherapeutics. Apigenin is inexpensive to ad-
minister and is non-toxic at pharmacologic dosesmaking it possible to ad-
minister concurrently with other chemotherapeutics while avoiding
additive toxicity [2]. Apigenin has been shown to inhibit pancreatic cancer
cell growth in vitro by induction of cell cycle arrest [3] and leads to syner-
gistic effects when combinedwith gemcitabine by inhibiting pro-survival
pathways involving pAKTwhich can contribute to gemcitabine resistance
[4]. Breast and colon cancer cells respond similarly to apigenin treatment
with cell cycle arrest and apoptosis inductionwhich is linked to increased
phosphorylation of p53 in bothwild type andmutant p53-expressing cell
lines [5,6]. Modulation of p53 activity appears to be central to the effec-
tiveness of apigenin: mechanistic studies utilizing osteosarcoma cells
identiﬁed phosphorylation of p53 at threonine 55 as a stimulus for nucle-
ar export—and thus deactivation of wild type p53 which was speciﬁcally
reversed by apigenin treatment [7].
However, the role of mutant p53 in cancer cells is multi-fold and
exceedingly complex. In its native state, p53 is known to act as a tran-
scription factor responsible for regulating the expression of cell-cycle
regulatory genes such as p21/waf, and cell-death inducing proteins
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from UV exposure or chemical insult and initiates either DNA-repair
or cell death machinery through its transcription-dependent regula-
tion of gene transcription. More recently alternative roles of p53
have been discovered involving p53-Upregulated Modulator of Apo-
ptosis (PUMA) and the mitochondrial pathway of programmed cell
death [9]. Interactions between PUMA, p53, and anti-apoptotic Bcl-
2-family proteins such as Bcl-XL have been described in which p53
acts outside of the nucleus in a transcription-independent fashion.
There is a poor understanding of the degree to which mutant p53 re-
tains its transcription-dependent and -independent functions in pan-
creatic cancer cells [10]. Furthermore, in addition to loss of tumor
suppressor functions, recent studies have identiﬁed gain of function
properties of mutant p53 involving activation of proliferative and
anti-apoptotic pathways and genes responsible for drug resistance
[11].
Given the complexity of the roles p53 plays in tumorogenesis and
aggressive tumor biology, the use of apigenin to re-establish or aug-
ment the growth-inhibitory and pro-apoptotic activity of mutant p53
could be a powerful strategy to check the growth of pancreatic cancer
and improve the effectiveness of existing chemotherapeutics. We hy-
pothesized that apigenin inhibits pancreatic cancer growth through re-
constitution of mutated p53 function in pancreatic cancer cells, thereby
inhibiting cancer cell proliferation and inducing apoptosis.
2. Methods
2.1. Cell culture and reagents
Human pancreatic cancer cell lines (MiaPaCa-2, BxPC-3) were
obtained from American Type Culture Collection (ATCC) and main-
tained in DMEM (MiaPaCa-2) or RPMI culture medium (BxPC-3)
(Invitrogen; Carlsbad, CA) supplemented with 10% fetal bovine
serum and 1% penicillin–streptamycin. Cells were cultured under
standard culture conditions. All solvents and regents for HPLC were
HPLC grade (Fisher Scientiﬁc, Fairlawn, NJ). Luteolin, quercetin and
β-glucuronidase/sulfatase (type H-5 from Helix Pomatia) were pur-
chased from Sigma-Aldrich (St. Louis, MO). Apigenin (Purity ≥98%;
Cayman Chemical, Ann Arbor, MI) and Piﬁthrin-α (Purity ≥95%;
Sigma-Aldrich, St. Louis, MO) were dissolved in DMSO as stock solu-
tions and stored at −20 °C for in vitro experiments. Antibodies for
total p53, phosphorylated p53 (ser-392), topoisomerase I, and Pro-
tein A-agarose beads were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA); antibodies for acetylated p53 (lys-382), PUMA, and
p21 were obtained from AbCam (Cambridge, MA); and antibodies for
GAPDH, Cox IV, Bcl-XL, Bax, and Bak were purchased from Cell Signal-
ing Technology (Boston, MA).
2.2. Growth inhibition assay
Cells were seeded onto 96-well plates at 104cells/well and
allowed to attach overnight at 37 °C. Cells were serum starved using
FBS-free DMEM or RPMI and allowed to grow for another 24 h at
37 °C after which varying concentrations of Apigenin±piﬁthrin-α
were incubated for 24 or 48 h. For growth inhibition, MTT (3-[4,5-Di-
methyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide; Sigma-
Aldrich, St. Louis, MO), was added for 3 h, cells solubilized in DMSO,
and plates were read with an ELISA reader at 560 nm.
2.3. Apoptosis detection assay
Cells were plated to 6-well plates at 5×105cells/well and allowed
to attach overnight at 37 °C. Cells were serum starved as above and
allowed to grow for 24 h at 37 °C followed by treatment as for growth
inhibition assays. Ultraviolet (UV) irradiation was performed by ex-
posing cells without medium with a standard UV lamp (SylvaniaG30T8, 30 W; Danvers, MA) for a total dose of 50 mJ/cm2. Medium
was replaced following exposure and cells harvested as for apigenin
and control-treated cells. A commercially available cell death detec-
tion ELISA kit (Roche Diagnostics, Mannheim, Germany) detecting
nucleosomes in the cytoplasm was used according to instructions.
Brieﬂy, cells were harvested by trypsinization, counted, and 104
cells were subjected to lysis. Lysate was added to microplate wells
coated with streptavidin along with anti-histone antibody conjugated
with biotin and anti-DNA antibody conjugated with horseradish per-
oxidase (HRP) and incubated. Substrate was added and plates were
read with an ELISA reader at 405 nm. Enrichment Factor (EF) was cal-
culated as a ratio of absorbance of treated cells versus that of
cells treated with vehicle alone (DMSO). EF=absorbance of sample/
absorbance of vehicle control.
2.4. Whole cell lysate and western blotting
Cells were grown on 10 cm dishes in standard cell culture condi-
tions to 80% conﬂuence and were serum starved overnight. Cells
were treated with apigenin±piﬁthrin-α or UV irradiation and were
incubated for 30 min to 48 h. Cells were washed twice with ice-cold
PBS and then underwent lysis with ice cold RIPA buffer containing
Protease and Phosphatase Inhibitor Cocktail (Thermo Scientiﬁc, Rock-
ford, IL). Cells were disrupted by repeated aspiration through a 23 G
needle prior to centrifugation at 14,000×g for 10 min at 4 °C. Pellet
was discarded and protein concentration determined by DC Protein
Assay (BioRad, Hercules, CA). Proteins (20 μg/well) were separated
on 10–15% SDS-polyacrylamide gel and transferred to nitrocellulose
membranes. The membranes were blocked with 5% nonfat dry milk
and probed with primary antibody overnight at 4 °C followed by sec-
ondary antibody. Bands were visualized by chemiluminescence sub-
strate (Thermo Scientiﬁc, Rockford, IL) and autoradiography. Digital
image analysis was performed with QuantityOne software (BioRad,
Hercules, CA).
2.5. Nuclear extraction
Cells were treated as above for western blotting. Cells were
washed twice with ice-cold PBS and then incubated with cold lysis
buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, 0.1% NP-40, 2 mM activated Na3VO4, 3 μg/mL Aprotinin, 25 μg/
mL Leupeptin, 25 μg/mL Pepstatin, 25 μg/mL Chymostatin, 0.2 mM
PMSF, and 5 mM NaF) for 10 min on ice. Cells were collected and sol-
ubilized by pipetting up and down followed by centrifugation at
16,000 ×g for 5 min at 4 °C. Cytosolic supernatant was aspirated and
stored at−80 °C. Nuclear pellet was solubilized in nuclear lysis buffer
(20 mM HEPES [pH 7.9], 1.5 mM MgCl2, 420 mM NaCl, 0.5 mM DTT,
25% glycerol, 2 mM activated Na3VO4, 3 μg/mL Aprotinin, 25 μg/mL
Leupeptin, 25 μg/mL Pepstatin, 25 μg/mL Chymostatin, 0.2 mM
PMSF, and 5 mM NaF) and incubated for 20 min on ice followed by
centrifugation at 16,000 ×g for 5 min at 4 °C. Protein concentration
was determined and samples were stored at −80 °C prior to either
western blotting or p53 binding activity assay.
2.6. Mitochondrial extraction
Cells were treated as above for western blotting. Cells were trypsi-
nized, collected, and centrifuged at 370 ×g for 5 min. Cells were
washed with ice-cold NKM buffer (1 mM Tris–HCl [pH 7.4], 0.13 M
NaCl, 5 mM KCl, 7.5 mM MgCl2) and re-centrifuged at 370 ×g for
5 min. Wash step was repeated once and then cell pellet was resus-
pended in homogenization buffer (10 mM Tris–HCl [pH 6.7], 10 mM
KCl, 0.15 mM MgCl2, 1 mM PMSF, 1 mM DTT) and incubated for
10 min on ice. Cells were broken by 20 strokes of a Dounce homoge-
nizer and incubated with 2 M sucrose for 10 min on ice followed by
centrifugation at 1200 ×g for 5 min at 4 °C. The pellet was discarded
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7000 ×g for 5 min at 4 °C. Cytoplasmic supernatant was aspirated and
stored at −80 °C. The pellet was re-suspended in mitochondrial sus-
pension buffer (10 mM Tris–HCl [pH 6.7], 0.15 mMMgCl2, 0.25 M su-
crose, 1 mM PMSF, 1 mM DTT) and centrifuged at 9500 ×g for 5 min
at 4 °C to pellet mitochondria. Pellet was resuspended in mitochon-
drial suspension buffer, protein quantiﬁed with DC protein assay,
and stored at −80 °C.
2.7. p53 binding activity assay
Binding activity of nuclear extracts was assayed with Human Ac-
tive p53 Activity Assay (R&D Systems, Minneapolis, MN) according
to manufacturer's instructions. Brieﬂy, nuclear extracts (20 μg of
total protein/well) were incubated with a biotin-labeled oligonucleo-
tide corresponding to a consensus p53-binding sequence on ice. Sam-
ples were then added to microplate wells coated with a p53 capture
antibody. Wells were treated with Streptavidin-HRP and the plate
was read with an ELISA reader at 450 nm.
2.8. Co-immunoprecipitation
Cells were treated as above for western blotting. Cells were
washed twice with ice-cold PBS and then incubated with cold lysis
buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, 0.1% NP-40, 2 mM activated Na3VO4, 3 μg/mL Aprotinin, 25 μg/
mL Leupeptin, 25 μg/mL Pepstatin, 25 μg/mL Chymostatin, 0.2 mM
PMSF, and 5 mM NaF) for 10 min on ice. Cells were collected and sol-
ubilized by pipetting up and down followed by centrifugation at
16,000 ×g for 5 min at 4 °C. Lysate was pre-cleared with normal rab-
bit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) and protein A-
Agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA). Beads
were pelleted by centrifugation at 1000 ×g for 5 min at 4 °C and pro-
tein quantiﬁed in the supernatant using DC protein assay. Lysate
(250 μg total protein) was incubated with primary antibody for one
hr on ice followed by addition of protein A-Agarose beads and incuba-
tion at 4 °C overnight on a rocker platform. Beads were pelleted by
centrifugation at 1000 ×g for 5 min at 4 °C and pellet was washed
with PBS+1% Tween-20 four times, pelleting beads by centrifugation
each time. Resulting pellet was resuspended in Laemmli buffer and
boiled at 95 °C for 10 min prior to centrifugation at 1000 ×g for
10 min to pellet beads. Proteins were separated and visualized by
SDS-PAGE as above for western blotting.
2.9. Cytochrome c immunoﬂuorescence
Cells were treated as above for western blotting. Cells were trypsi-
nized, collected, and centrifuged at 1000 ×g for 10 min. A commer-
cially available kit was used to perform immunoﬂuorescence for
cytochrome c (EMD Chemicals, Darmstadt, Germany). Brieﬂy, 106
cells were resuspended in permeabilization buffer and incubated for
10 min on ice. Cells were ﬁxed with 8% paraformaldehyde for 5 min
and pelleted by centrifugation at 1000 ×g for 5 min. Cells were
washed ×3 with wash buffer, repeating centrifuge step each time,
and then incubated with blocking buffer for 1 h. Samples were incu-
bated with primary antibody followed by secondary antibody and
then pelleted as above. Cells were resuspended in wash buffer and
mounted on a microscope slide with Vectashield HardSet mounting
medium+DAPI (Vector Labs, Burlingame, CA) and visualized with
immunoﬂuorescence microscopy.
2.10. Experimental animals
All animal experiments were performed according to protocols
approved by the Chancellors Animal Research Committee at UCLA.
Twelve four week-old male nude mice (Nu/Nu) were obtained fromCharles River Laboratories (Wilmington, MA) and provided standard
γ-irradiated rodent chow and autoclaved water ad libitum prior to
orthotopic xenograft experiments.
2.11. Orthotopic xenograft model of pancreatic cancer
Human pancreatic cancer cells (MiaPaCa-2) were grown to 80%
conﬂuence, trypsinized, and counted. Cells were resuspended in
serum free DMEM supplemented with 30% growth factor reduced
Matrigel (BD Biosciences, San Jose, CA). Mice (n=6 treatment;
n=6 control) were anesthetized with inhaled isoﬂurane (Phoenix
Pharmaceutical, St. Joseph, MO), skin was prepared with Betadine
(Purdue Products, Stamford, CT), and a one cm paramedian laparoto-
my in the left abdomen created. The spleen and tail of the pancreas
was exteriorized and 5×105 cells injected into the tail of the pancre-
as. The viscera were reoriented within the abdomen and the wound
closed in two layers with sutures.
2.12. Dietary supplementation with apigenin and tissue procurement
Apigenin (Purity≥98%) wasmixed with powdered AIN-76A rodent
diet (Dyets; Bethlehem, PA) for in vivo feeding experiments. Animals
were provided with either control diet (six animals; AIN-76A reconsti-
tutedwith autoclavedwater alone) or 0.2% apigenin-supplemented diet
(six animals; AIN-76A+0.2% apigenin [w/w] reconstituted with auto-
claved water) ad libitum for 6 weeks following orthotopic xenograft
tumor implantation. Apigenin dose was calculated based on pilot feed-
ing experiments in which we assessed feeding tolerance and potential
toxicity aswell as apigenin levels in the serum and tissues. Feed supple-
mented with 0.2% apigenin was tolerated well by mice with no noted
toxicity and tissue levels were detectable in the tens—of micromoles
per liter—a level which showed cytotoxic effects in in vitro experiments
(data not shown). Feedwas replaced every-other day and intake of feed
was measured daily. Mice were weighed weekly. At the end of the six
week study period mice were sacriﬁced and tissues collected. Plasma
was collected by exsanguinating cardiac puncture. Ten microliter hepa-
rin (1000 U/mL) was added to 1 mL of whole blood and centrifuged at
500 ×g for 10 min at 4 °C. Plasma was mixed with 10% (v/v) 0.58 M
acetic acid and stored at−80 °C. Liver, pancreas, and tumor specimens
were snap frozen in liquid nitrogen and stored at −80 °C. Additional
liver, pancreas, and tumor specimens were ﬁxed in 10% paraformalde-
hyde, parafﬁn embedded, and sectioned for immunohistochemical
analysis.
2.13. Immunohistochemistry
Parafﬁn-embedded tissue sections (4 μm) were dewaxed and rehy-
drated in xylene and graded ethanol washes followed by deionized
water and stained with the TUNEL method. Apoptosis was quantiﬁed
by counting the number of TUNEL positive cells per 100 cells in 10 ran-
dom microscopic ﬁelds (400×; 1000 cells counted/sample; control
[n=6] and 0.2% apigenin-fed [n=6]).
2.14. HPLC for detection of apigenin in plasma and tumor samples
Plasma samples were acidiﬁed with 10% (v/v) 0.58 M acetic acid to
limit ﬂavonoid losses. Acidiﬁed plasma samples were further prepared
with 0.2 M sodium acetate buffer (pH 5.0) with 1% ascorbic acid, β-
glucuronidase, and sulfatase. The resulting mixture was vortexed and
then incubated at 37 °C for 2 h. After incubation, ethyl acetate was
added followed by 10 μL quercetin in MeOH as an internal standard.
Apigenin and its metabolites were extracted with 800 μL ethyl acetate
three times. In each extraction mixture was vortexed for 1 min and
then centrifuged at 600 rpm for 5 min. Supernatant was transferred to
a glass test tube and combined. Solvent was removed in a SpeedVac at
room temp until completely dry. Residue was reconstituted in 100 μL
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icated for 1 min. An aliquot of 50 μL supernatant was injected into the
HPLC column.
For tissue sample analysis, frozen tissue was weighed and homoge-
nized in sodium acetate buffer with a tissue grinder and internal stan-
dard was added. The mixture was then hydrolyzed and extracted
similar to plasma samples. HPLC analysis was performed with a RP-18
Luna column (150×4.6 mm, 3 μm, Phenomenex, Torrance, CA) on an
Agilent 1100 HPLC system comprising of an autosampler, a quaternary
pump and a photodiode array detector (Agilent Technologies, Palo
Alto, CA). The mobile phase consisted of a binary gradient of 0.1% (v/v)
ortho-phosphoric acid in water (eluent A) and methanol (eluent B),
used with ﬂow rate of 0.5 mL/min in the following conditions: 50–80%
B (0–12 min); 80% B (12–17 min); and 80–50% B (17–20 min). Column
temperature was held on 28 °C. The chromatograms were recorded at
337 nm and 255 nm for apigenin and its metabolites.
Data were analyzed with the Hewlett Packard Chemstation® soft-
ware. Mouse plasma and tissue concentrations were determined by
internal calibration. Concentration of the stock solutions was deter-
mined spectrophotometrically using Beer's Law. Calibration stan-
dards were prepared from the stock solutions by series dilution. The
calibration curves generated from standard solutions of apigenin
showed a linear relationship between peak area and concentration
in the range of 22.07 ng/mL to 5.65 μg/mL. The limit of quantitation
for apigenin was 11.0 ng/mL. Stability of apigenin in mouse diet was
measured at 0, 1, 2, and 3 days following preparation by HPLC follow-
ing excessive extraction with methanol.
2.15. Statistical analysis
Descriptive statistics such as mean and standard error (SE) were
summarized for all variables using bar plots. P values were calculated
with two-tailed t-test and statistical signiﬁcance reached at the
p≤0.05 level. For analysis of animal studies, logarithm transformation
was applied to pancreas total apigenin and plasma free apigenin to im-
prove normality. Two sample t-tests were performed to study the treat-
ment effect of 0.2% apigenin relative to control for tumorweight. Scatter
plots were used to illustrate patterns of tumor weight with respect to
log-transformed pancreas total apigenin and log-transformed plasma
free apigenin respectively, as well as the pattern of log-transformed
pancreas total apigenin with respect to log-transformed plasma free
apigenin. Pearson's correlation coefﬁcients and p-values for testing
the null hypothesis of no correlation were reported.
3. Results
3.1. Apigenin inhibits pancreatic cancer cell growth and induces apoptosis
in vitro
MiaPaCa-2 and BxPC-3 cells treated with apigenin at concentrations
of 1–100 μM resulted in dose-dependent decrease in cell proliferation
as detected by MTT with an IC50 of ~25–50 μM for MiaPaCa-2 and ~1–
10 μMfor BxPC-3 at 24 h following treatment. Inhibition of proliferation
was time-dependent aswell (Fig. 1A and B). These datawere conﬁrmed
by cell counts with trypan blue staining and 5-Bromo-2′-deoxy-uridine
(BrdU) incorporation ELISA (Supplemental Fig. 1A and B). There was a
7.7±2.9-fold increase in apoptosis for MiaPaCa-2 cells treated with
25 μM apigenin for 24 hours and 16.5±5.0-fold increase for similarly
treated BxPC-3 cells (Pb0.05; Fig. 1C). This exceeded the amount of ap-
optosis for cells treated with UV irradiation (50 mJ/cm²).
3.2. Apigenin modulates post-translational modiﬁcation, nuclear translo-
cation, and DNA binding of p53
Apigenin treatment led to increased acetylation of lysine 382
(75.8±12.5% at 8 h, Pb0.05; Fig. 2A)—a signal associated with nucleartranslocation and stabilization of the p53 tetramer. Increased acetyla-
tion followed a time course that showed a peak at 4 to 8 h for BxPC-3
and MiaPaCa-2 cells, respectively—though a measurable increase in
acetylation was observed as early as 30 min following treatment with
25 μM apigenin (25.6±9.3% increase). Accordingly, nuclear extracts
showed increased levels of p53 protein relative to cytoplasmic extracts
peaking at 2 h following apigenin treatment (52.4±8.9% increase,
Pb0.01; Fig. 2B), indicating nuclear translocation of p53. Nuclear trans-
locationwas also accompanied by increased p53 binding to a consensus
promoter sequence detected by ELISA despite the presence of mutated
p53 in both cell lines tested (MiaPaCa-2 65.8±0.6% increase and BxPC-
3 48.9±0.3% increase, Pb0.01; Fig. 2C). These events were all in the
context of a slight decrease in p53 expression observed inwhole cell ly-
sates (24.3±3.5% decrease at 12 h, Pb0.01; Fig. 2D). These data indicate
that treatment with apigenin may increase the ability of p53 to bind to
promoter regions of targeted genes and thus partially restore the func-
tion of themutant p53 protein. Interestingly themagnitude of increased
p53DNAbindingwas similar for both cell lines indicating the possibility
of additional mechanisms responsible for the anti-proliferative effects
of apigenin.
3.3. Apigenin-induced apoptosis is not dependent on p53-mediated tran-
scriptional regulation
In non-neoplastic cells, p53 activation has been shown to cause
cell cycle arrest and cell death via activating expression of numer-
ous cell cycle and/or apoptosis mediators such as p21 and PUMA
(p53 Upregulated Mediator of Apoptosis). These proteins then me-
diate downstream events such as cyclin-dependent kinase inhibi-
tion (p21) and caspase activation (PUMA). Apigenin treatment
(25 μM) induced the expression of p21 and PUMA, consistent with
our data showing nuclear translocation and increased DNA binding
of p53 (Fig. 3A). This upregulation was blocked by the addition of
25 μM piﬁthrin-α (PFT), a speciﬁc inhibitor of p53 DNA binding
(Fig. 3B). However, the anti-proliferative effect of apigenin was
not reversed by treatment with piﬁthrin-α nor was increased apo-
ptosis (Fig. 3C,D) indicating that apigenin may activate p53 through
a parallel, transcriptionally independent pathway of programmed
cell death.
3.4. Apigenin induces mitochondrial translocation and modulates
protein–protein interaction of p53 and PUMA with Bcl-XL
Consistent with a model of transcriptionally-independent p53
activation we found there was increased translocation of p53 to
the mitochondria in apigenin-treated cells (31% increase; Fig. 4A).
Immunoprecipitation of the anti-apoptotic Bcl-2 protein Bcl-XL
showed there was dissolution of complexes between Bcl-XL/p53
and Bcl-XL/PUMA following apigenin treatment. Binding of p53
and PUMA with Bcl-XL effectively sequestered these molecules in
the unstressed cells (Fig. 4B). Following liberation from Bcl-XL, p53
and PUMA both formed stable complexes with Bak leading to mito-
chondrial membrane permeabilization and cytochrome c release
seen by immunoﬂuorescence (Fig. 4C).
3.5. Dietary apigenin reduces the volume of orthotopic pancreatic cancer
xenografts in nude mice
Using a well-established nude mouse model of human pancreatic
cancer we tested the hypothesis that dietary apigenin supplementa-
tion would yield smaller pancreatic tumors compared to mice fed
standard rodent diet. All mice fed and gained weight appropriately
with no gross evidence of toxicity. Serum chemistries were per-
formed at the conclusion of the feeding period and there were no sig-
niﬁcantly elevated indices among a panel testing for pancreatic,
renal, and hepatic function. Finally, feed samples were tested for the
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Fig. 1. Apigenin inhibited pancreatic cancer cell growth dose- and time-dependently for MiaPaCa (A) and BxPC-3 (B) cells. Apigenin dose-dependently induced apoptosis for MiaPaCa
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of apigenin over 72 h at ambient humidity and temperature (data not
shown).
Apigenin-fed mice had signiﬁcantly elevated levels of apigenin
detected in both plasma (0.3±0.04 vs. 0.2±0.01 μg/mL, Pb0.05;
Fig. 5A) and tumor (1.8±0.7 vs 0.2±0.1 mg/g tissue, Pb0.05; Fig. 5B).
Tumors tended to be smaller in apigenin-fed mice (0.7±0.1 vs. 0.9±
0.1 g, P=0.058, Fig. 5C) and there was a strong correlation between
tumor apigenin level and tumor size (Pearson correlation coefﬁcient
−0.65, Pb0.05; Fig. 5D) indicating mice that ingested the most apigenin
had the smallest tumors. TUNEL staining performed on tumor sections
demonstrated an increased proportion of apoptotic cells for the treated
tumors (56.3±6.2 vs. 33.2±8.3 TUNEL positive cells/HPF; Pb0.05;
Fig. 6).
4. Discussion
Our initial growth inhibition and apoptosis experiments indicated
that apigenin exhibited potent anti-proliferative and pro-apoptotic
effects on pancreatic adenocarcinoma cells in vitro. These results are
consistent with prior reported work with pancreatic cancer cellstreated with apigenin. The concentrations of apigenin required to in-
hibit growth and induce apoptosis were somewhat higher than those
attained in in vivo murine experiments. Several factors may contrib-
ute to this phenomenon: cell culture experiments were performed
in serum-free medium where the solubility of apigenin is limited, ef-
fectively decreasing its bioavailability in vitro [12]. Additionally, phar-
macologic studies of apigenin have shown that apigenin sequesters in
the lipid fraction of organs; the resulting high volume of distribution
makes the serum concentration of apigenin a relatively small compo-
nent of the total apigenin level in vivo [13]. These variables may in-
crease the apparent IC50 in vitro by necessitating a large amount of
apigenin dissolved in the medium to attain the same total apigenin
concentration seen in vivo.
p53 has long been recognized to be a critical factor in cell cycle
progression and apoptosis in untransformed cells following genotoxic
insults such as UV or gamma irradiation [14]. Furthermore mutation
of the Tp53 gene has been implicated as a transformative factor in nu-
merous human malignancies, including pancreatic adenocarcinoma
where it is mutated in up to 76% of resected tumors and 67% of estab-
lished cell lines [15,16]. MiaPaCa-2 and BxPC-3 cells have Tp53 muta-
tions in codons corresponding to the DNA-binding domain of the
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Mutations in these codons are the most commonly seen alterations
of the Tp53 gene for pancreatic cancers as well as many other typesof human malignancy. There is evidence that these mutations may
have characteristic functional consequences affecting protein half-
life, conformation, and DNA sequence-speciﬁcity [18]. Tp53 mutation,
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599J.C. King et al. / Biochimica et Biophysica Acta 1823 (2012) 593–604along with activating mutation of Kras, is thought to be a key event in
pancreatic carcinogenesis. Importantly, the MiaPaCa-2 cell line has
mutated Kras while BxPC-3 is unusual in that it has a wild-type
gene. Given both cell lines ultimately respond to apigenin treatment
we surmised that apigenin may act through a mechanism indepen-
dent of Kras. For this reason, our choice of both Kras mutant and
wild-type cell lines was helpful in directing our investigation away
from the RAS/RAF/MAPK pathway. We chose to study p53 because
it is a key molecule uniquely situated in cellular machinery responsi-
ble for both cell cycle inhibition and apoptosis induction. Further-
more, we hypothesized that loss-of-function mutations in Tp53 seen
in pancreatic cancer may be partially circumvented by treatmentwith apigenin leading to cell cycle arrest and apoptosis seen in
in vitro growth assays.
In the current study, in vitro experiments demonstrated
transcription-dependent functionality of p53 despite the presence of
deactivating mutations in the Tp53 gene in both cell lines tested.
This ﬁnding is in concordance with previous reports in the literature
studying the effect of apigenin in widely disparate cancer cell lines,
including carcinoma and sarcoma cell lines [5–7]. Apigenin treatment
was accompanied by increases in acetylation of lysine-392. This mod-
iﬁcation is carried out by the acetyltransferases CBP/p300 and is
known to affect p53 sequence-speciﬁc DNA binding and p53 half-
life [19]. Consequently, binding of p53 to DNA was also promoted
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600 J.C. King et al. / Biochimica et Biophysica Acta 1823 (2012) 593–604by apigenin treatment. p53 fulﬁlled its classically described role as an
activator of transcription of the cell cycle regulatory gene p21 and the
pro-apoptotic gene PUMA correlating to our ﬁndings of decreased
cellular proliferation and increased apoptosis. Importantly, this tran-
scriptional activation was promoted by apigenin treatment and
completely abrogated by co-treatment with piﬁthrin-α—a speciﬁc
inhibitor of p53/DNA binding—indicating p53 transcriptional
activation was causally related to apigenin treatment.Based upon these results apigenin appeared to restore the
transcription-dependent activation of p53. However, we did not ﬁnd
a correlation between the relative sensitivity of the two cell lines
to apigenin's anti-proliferative and pro-apoptotic effects to the in-
crease in p53 activation (i.e.: BxPC-3 IC50 was two-to-ﬁve fold lower
than MiaPaCa-2 while p53-DNA binding was similar). Furthermore,
we found there was very little reversal of the anti-proliferative and
pro-apoptotic effects of apigenin when transcription-dependent p53
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sibility of parallel pathway(s) involving the [co-] activation of PUMA
as has been demonstrated in neoplastic and non-neoplastic cells
with intact p53 function [20,21].
Currentmodels of the p53/PUMA apoptotic pathway describe disso-
lution of the p53/Bcl-XL complex accompanied by creation of a PUMA/
Bcl-XL pair which is required for ‘freeing’ p53 prior to its activation of
the downstream BH123 proteins such as Bax or Bak [20]. These ﬁndings
were reported by Chipuk et al. using HCT116 colorectal carcinoma cells
and mouse embryonic ﬁbroblasts which express wild-type p53. Both
nuclear p53, which incites transcriptional activation of PUMA, as well
as cytosolic p53, which binds to and activates Bax, are necessary for in-
duction of apoptosis in this model as shown by the lack of PUMA-
mediated apoptosis in p53 null cells. This model has been disputed by
Callus et al who observed continued PUMA-mediated apoptosis in
p53-null mouse embryonic ﬁbroblasts and murine myeloid cell lines
undergoing forced overexpression of PUMA (thus obviating the need
for p53-mediated transcriptional upregulation of PUMA) and con-
tended that the role of p53 in PUMA-mediated apoptosis was limited
to transcriptional upregulation of PUMA [22].
Our results indicate that there may be a combination of these two
models of transcription-independent p53 function in pancreatic cancer
cell lines. Apigenin treatment resulted in increased expression of PUMA
(via p53 transcriptional activation) and co-immunoprecipitation dem-
onstrated dissociation of stable complexes between both p53/Bcl-XL
and PUMA/Bcl-XL, indicating that p53 and PUMA may act in parallel to
activate Bax following dissociation from Bcl-XL. In the case of PUMA/Bcl-XL, there was no detectable complex following treatment with api-
genin as opposed p53/Bcl-XL where therewas a partial dissolution. This
ﬁnding is supported by structure/function and afﬁnity binding studies
which have shown that p53—though it lacks a true BH3 domain—
binds to Bcl-XL through its DNA binding domain to the ‘bottom side’
of Bcl-XL—at residues distinct from its BH3 domain [23]. The dissocia-
tion constant for the p53/Bcl-XL complex was 164±54 nM KD versus
10±4 nM KD for PUMA/Bcl-XL [20].
Once p53 and PUMA are freed from sequestration by Bcl-XL both
formed complexes with pro-apoptotic Bak, suggesting both proteins
act as BH3-only molecules in this situation. These events appear to
occur in parallel in contrast to the ﬁndings of Chipuk et al in which
p53 and PUMA ‘ﬂip-ﬂop’ their association with Bcl-XL so that p53
can then activate pro-apoptotic Bax [20].
Further support for this model comes from studies in which another
polyphenolic ﬂavonoid, rottlerin, was found to alter interactions of Bcl-
XL with the BH3-only proteins PUMA and Bim in a manner similar to a
known Bcl-XL inhibitor, BH3I-2′ which preferentially binds to the
hydrophobic pocket of Bcl-XL, preventing its binding with BH3-only pro-
teins [24]. These experiments were performed in the MiaPaCa-2 and
Panc-1 pancreatic cancer cell lines, making their ﬁndings directly applica-
ble to this study. Based on these data we propose that apigenin induces
dissociation of p53 and PUMA from sequestration by Bcl-XL allowing acti-
vation of Bak by both p53 and PUMA at the mitochondrial membrane
leading to cytochrome c release and initiation of the caspase-drivenmito-
chondrial cell death cascade as has been shown by others [25]. Release of
p53 from Bcl-XL appears to have the added effect of nuclear translocation
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PUMA. However, the transcriptionally-dependent function of p53 does
not appear to be necessary for induction of apoptosis (Fig. 7). It is not
clear whether apigenin's effect is direct through its binding to p53,
PUMA, or Bcl-XL or indirect via its known ability to inhibit the activity of
numerous kinases including PKC, PI3-kinase, and the JAK/STAT pathway
[26,27]. Additional experiments utilizing a p53 null cell line, or ‘knock-
down’ of p53 may help to further elucidate the role of p53 in the mecha-
nism of apigenin.
Our in vivo studies were designed to demonstrate the efﬁcacy of
apigenin as an orally administered chemotherapeutic. Our primary
outcome measure was tumor size following 6 weeks of dietary sup-
plementation of apigenin. While the tumors in treated animals were
smaller than control diet-fed mice this difference was not statistically
signiﬁcant (P=0.058). Correlation of apigenin levels with tumor size
showed a signiﬁcant reduction in tumor volume in mice with the
highest tissue levels of apigenin. Because apigenin was administered
as a dietary supplement ad libitum (as opposed to gavage feed),
mice that ate more feed were exposed to greater doses of apigenin
and may have achieved higher tissue levels. This along with individu-
al differences in absorption and elimination of apigenin and the dose-
dependency of apigenin's anti-neoplastic properties contributed to
the inhomogeneity of the data, and the apparent lack of treatment ef-
fect when examining tumor volume alone. The small sample sizes(n=6 treatment, n=6 control mice) also may have contributed to
the lack of signiﬁcance through type II error (accepting null hypothe-
sis when treatment effect truly exists due to insufﬁcient sample size).
While the administration method employed may be seen as a weak-
ness in our study design it does allow us to conclude that apigenin
supplementation at a level known to be non-toxic and well-
tolerated (as opposed to mega-doses that may be intolerable or oth-
erwise unachievable in human subjects) can have a positive effect
on tumor size and lead to increased tumor apoptosis as seen with
TUNEL staining.
Further study is warranted, particularly in the area of apigenin as a
supplemental therapy in combination with standard chemotherapeu-
tics such as gemcitabine. Studies have indicated a facultative role of
apigenin in increasing the efﬁcacy of gemcitabine's anti-tumor effects
[4,28]. This polypharmacy strategy may also help to improve the tol-
erability of chemotherapeutic regimens by reducing the dose neces-
sary to realize a treatment effect. It is not known whether apigenin
would have a similar effect when combined with newer chemothera-
py combinations. At least one study has indicated that apigenin may
actually decrease the effectiveness of standard chemotherapeutics
necessitating a deeper understanding of the exact mechanism of api-
genin's effects and a more targeted approach to combination with
existing drugs [27]. Finally, apigenin may have chemopreventative
properties which would halt the progression of pre-neoplastic
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603J.C. King et al. / Biochimica et Biophysica Acta 1823 (2012) 593–604PanIN lesions to invasive carcinoma [29]. Apigenin's anti-neoplastic
properties as they relate to the timing of p53 mutation, which is
thought to be a late event in the dysplasia-carcinoma continuum,
would be of particular interest in light of our ﬁndings here.
Although these data do not deﬁnitively establish a causal mecha-
nism between Bcl-XL, PUMA, and p53, they do indicate that the roles
of p53 and PUMA may be parallel and facultative, not sequential and
inexorably linked as has been previously proposed. Furthermore,
our data show that evenmutated p53 retains some of its cell cycle reg-
ulatory and pro-apoptotic function(s) in the presence of growth-
inhibitory stimuli such as apigenin treatment. Most importantly
from a translational perspective apigenin reduced the size of xeno-
graft tumors in a dose-dependent fashion with greater cellular apo-
ptosis, thus correlating in vitro observations with in vivo data. These
ﬁndings contribute additional support to a growing body of evidence
indicating apigenin may hold promise as a chemotherapeutic for the
treatment of pancreatic cancer.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2011.12.008.References
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